Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders

Table 2 The effects of pharmacological treatment of MSCs

Drug	Target cells	Clinical effect	MSC-mediated hematopoiesis	MSC-mediated bone regeneration	Mechanism(s) in MSCs	References
ASA	Broad cells	Anti-inflammation	N/T	↑	Telomerase activity↑	[33]
EPO	Erythroid progenitors	Erythropoiesis	↑	↑	EPOR/Stat5 pathway↑	[34]
PTH	Osteoblasts/Osteoclasts	Osteoporosis	↑	→	CDH11 expression↑	[35]
VK2	Osteoblasts	Osteoporosis	↑	↑	CXCL12 expression↓	[37]
OICS	N/A	Osteoporosis	↑	→	CXCL12 and VCAM1 expression↓	[36]

Up arrows indicate up-regulation or activation. Down arrows indicate down-regulation or inactivation
ASA acetylsalicylic acid (aspirin), EPO erythropoietin, EPOR erythropoietin receptor, MSC mesenchymal stromal/stem cell, N/T not tested, OICS osteo-inductive cocktail (dexamethasone, phosphate, and vitamin C ), PTH parathyroid hormone, VCAM1 vascular cell adhesion protein 1, VK2 vitamin K2

ISSN: 1880-8190